 |
|
|
|
|
|
 Introduction
Human
Veterinary
Environmental
Industrial
Agricultural
MSG
Introduction
Medical
Veterinary
Environmental
Industrial
Agricultural
Introduction
Susceptibility
MIC Database
Procedures
Histopathology
Introduction
Abbreviations
Links
CME
Conference
Highlights
Bibliography
Glossary
Good Books
Events Calendar
Introduction
Our Mission
Editorial Board
Editorial Staff
Supporters
Contributors
Legal Stuff
Privacy Policy
Kudos
Introduction
Descriptions
Synonyms
Image Bank
Lecture Bank
Video Bank
This page updated:
1/27/2007 9:23:00 AM
DoctorFungus - All Rights Reserved
© 2007 Copyright
& Privacy Policy
Site built and designed for doctorfungus by Webillustrated
|
 |
 |
|
|
You are here:
The Fungi
> Descriptions >
|
|
Candida glabrata
(Anderson) S.A. Meyer & Yarrow (Yarrow and Meyer 1978)
|
|
Colonies on Sabouraud dextrose agar at 25°C are white, smooth and glistening. This isolate grows at 42°C but fails to grow on media containing cycloheximide.
On cornmeal following 72 hours incubation at 25°C, only blastoconidia are observed. Yeast cells are quite small measuring only 2.5-4.0 x 3.0-6.0 µm as compared to C. albicans which measures 3.5-6.0 x 4.0-8.0 µm [1270].
Candida glabrata is known for its decreased susceptibility to azoles [1410] but good susceptibility patterns to candins [678], [1688]. Despite the decreased susceptibility to azoles, fluconazole prophylaxis has not contributed to an increased incidence of bloodstream infection caused by C. glabrata [1348]. This species do, however, contribute to mortality in approximately 21% of pediatric patients with bloodstream infections [773]. Although this species may be recovered from virtually all infection sites, recent reports of infection include corneal [37], endocarditis [1392], vaginitis [540], and oral [1882].
| AMB |
CAS |
5FC |
FLU |
ITRA |
VORI |
KETO |
| 0.125 µg/ml=23 |
0.06 µg/ml=311 |
<0.125 µg/ml=251 |
<0.125 µg/ml=4 |
<0.015 µg/ml=8 |
<0.015 µg/ml=8 |
0.06 µg/ml=4 |
| 0.25 µg/ml=501 |
0.125 µg/ml=419 |
0.25 µg/ml=9 |
0.25 µg/ml=6 |
0.03 µg/ml=5 |
0.03 µg/ml=6 |
0.125 µg/ml=7 |
| 0.5 µg/ml=448 |
0.25 µg/ml=329 |
0.5 µg/ml=2 |
0.5 µg/ml=10 |
0.06 µg/ml=4 |
0.06 µg/ml=36 |
0.25 µg/ml=63 |
| 1.0 µg/ml=41 |
0.5 µg/ml=43 |
2.0 µg/ml=1 |
1.0 µg/ml=24 |
0.125 µg/ml=45 |
0.125 µg/ml=102 |
0.5 µg/ml=53 |
| 2.0 µg/ml=11 |
1.0 µg/ml=10 |
4.0 µg/ml=3 |
2.0 µg/ml=140 |
0.25 µg/ml=116 |
0.25 µg/ml=234 |
1.0 µg/ml=42 |
| 4.0 µg/ml=2 |
2.0 µg/ml=6 |
8.0 µg/ml=2 |
4.0 µg/ml=421 |
0.5 µg/ml=158 |
0.5 µg/ml=134 |
2.0 µg/ml=27 |
| 16 µg/ml=2 |
4.0 µg/ml=6 |
16 µg/ml=1 |
8.0 µg/ml=375 |
1.0 µg/ml=179 |
1.0 µg/ml=89 |
4.0 µg/ml=6 |
| |
8.0 µg/ml=3 |
|
16 µg/ml=229 |
2.0 µg/ml=76 |
2.0 µg/ml=61 |
8.0 µg/ml=2 |
| |
>16 µg/ml=10 |
|
32 µg/ml=127 |
4.0 µg/ml=79 |
4.0 µg/ml=71 |
|
| |
|
|
>64 µg/ml=199 |
>8.0 µg/ml=112 |
>8.0 µg/ml=19 |
|
| Drug/N |
AMB/1028 |
CAS/1138 |
5FC/266 |
FLU/1535 |
ITRA/782 |
VORI/781 |
KETO/204 |
| MIC Range |
0.125->16 |
0.06->16 |
<0.125-16 |
<0.125->64 |
<0.015->8.0 |
<0.015->8 |
0.06-8 |
| MIC50 |
0.25 |
0.125 |
< 0.125 |
8.0 |
1.0 |
0.5 |
0.5 |
| MIC90 |
0.5 |
0.25 |
< 0.125 |
> 64 |
8.0 |
4.0 |
2.0 |
* Fungus Testing Laboratory unpublished data (NCCLS M27-A2)
PubMed
GenBank
|
|
|
References
37. Al-Assiri, A., S. Al-Jastaneiah, A. Al-Khalaf, H. Al-Fraikh, and M. D. Wagoner. 2006. Late-onset donor-to-host transmission of Candida glabrata following corneal transplantation. Cornea. 25:123-125.
540. De Vos, M. M., M. Cuenca-Estrella, T. Boekhout, B. Theelen, N. Matthijs, T. Bauters, H. Nailis, M. A. Dhont, J. L. Rodriguez-Tudela, and H. J. Nelis. 2005. Vulvovaginal candidiasis in a Flemish patient population. Clin Microbiol Infect. 11:1005-11.
678. Ernst, E. J., E. E. Roling, C. R. Petzold, D. J. Keele, and M. E. Klepser. 2002. In vitro activity of micafungin (FK-463) against Candida spp.: Microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. 46:3846-3853.
773. Fridkin, S. K., D. Kaufman, J. R. Edwards, S. Shetty, and T. Horan. 2006. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics. 117:1680-1687.
1270. Kurtzman, C. P., and J. W. Fell (ed.). 2000. The Yeasts. A Taxonomic Study. Elsevier Scientific B.V., Amsterdam, The Netherlands.
1348. Lin, M. Y., Y. Carmeli, J. Zumsteg, E. L. Flores, J. Tolentino, P. Sreeramoju, and S. G. Weber. 2005. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother. 49:4555-60.
1392. Lye, D. C. B., A. Hughes, D. O'Brien, and E. Athan. 2005. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur. J. Clin. Microbiol. Infect. Dis. 24:753-755.
1410. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole cross-resistance among Candida spp.: Case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol. 44:529-535.
1688. Olson, J. A., J. P. Adler-Moore, P. J. Smith, and R. T. Proffitt. 2005. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob. Agents Chemother. 49:4895-4902.
1882. Redding, S. W., K. A. Marr, W. R. Kirkpatrick, B. J. Coco, and T. F. Patterson. 2004. Candida glabrata sepsis secondary to oral colonization in bone marrow transplantation. Med Mycol. 42:479-481.
|
|
|
 |
 |
Home |
Image Bank |
Lecture Bank |
Knowledgebase |
Site Map |
Contact Us |
The Fungi |
Mycoses |
Drugs |
Laboratory |
Education & Tools |
About Us
|
|
|
|